Drug Profile
Pegfilgrastim biosimilar - Hangzhou Jiuyuan Gene Engineering
Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Hangzhou Jiuyuan Gene Engineering
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 02 Jun 2020 Hangzhou Jiuyuan Gene Engineering and Cancer Hospital Chinese Academy of Medical Sciences plan a phase III trial for Neutropenia (Prevention, Chemotherapy-induced) in China (Parenteral, Injection) in August 2020 (ChiCTR2000033478)
- 19 Nov 2018 No recent reports of development identified for phase-II for Neutropenia (In adults, In the elderly) in China (SC)
- 01 Jul 2013 Phase-II clinical trials in Neutropenia (Prevention, Chemotherapy-induced) in China (SC)